Abstract
Introduction
Epilepsy is one of the most prevalent neurological conditions and affects approximately 65 million people worldwide [1, 2] . It has been suggested that epileptic seizure results from abnormal neuron synchronization that disturbs normal neuronal communication and electrical discharges [2] . Increasing evidence also highlights that neuroinflammation, mediated by microglia and astrocytes in the brain, is an important contributor to neuronal hyperexcitability underlying seizure generation [3, 4] . Nevertheless, how these glial cells facilitate the development of seizures and epilepsy by increasing excitability and inflammation is yet to be fully elucidated.
MicroRNAs (miRNAs) are small (∼22 nt) noncoding transcripts that regulate gene expression by binding the 3′ untranslated regions of target mRNAs and reducing mRNA stability and translation [5, 6] . About 60% of all human proteins are estimated to be directly regulated by miRNAs [7] . Recent research suggests that miRNAs play key roles in the pathogenesis of a variety of neurological disorders, including epilepsy [8] [9] [10] [11] . Moreover, some miRNAs have been found differentially expressed in the brain under pathological conditions and might therefore represent both therapeutic targets and diagnostic or prognostic biomarkers for epilepsy [12] [13] [14] [15] .
MicroRNA-155 (miR-155) is a typical multifunctional miRNA and has been shown to play important roles in inflammation, immune responses, and tumorigenesis [16] [17] [18] [19] [20] . In the central nervous system, miR-155 has been found to be a major regulator of proinflammatory responses in immunity [21] [22] [23] . It was highly upregulated during macrophage inflammatory responses and in multiple sclerosis lesions [24, 25] . However, whether miR-155 and miR-155-mediated neuroinflammation contribute to epilepsy remains elusive.
In the current study, we aim to explore the role of miR-155 in epilepsy. We hypothesized that miR-155-mediated microglial inflammation promoted the epileptogenesis in epilepsy patients and kainic acid (KA)-induced seizure mice, and that attenuation of these proinflammatory processes by miR-155 ablation would attenuate the disease.
Materials and Methods
Reagents KA was purchased from Sigma-Aldrich. miR-155 antagomir and its scrambled negative control (NC) as well as primers for mouse or human U6, miR-155, miR-338, miR-200b , and miR-23a were from RiboBio (Guangzhou, China). Primers for mouse Snx27, il-6, il-1β, and β-actin were all from Sangon Biotech (Shanghai, China).
Clinical Samples
All of the clinical samples were collected at Affiliated Zhongshan or Chenggong Hospital of Xiamen University. Brain samples from 12 temporal lobe epilepsy (TLE) patients and 11 patients with temporal vascular malformation but no history of epilepsy or other neurological diseases were stored in an ultra-low-temperature freezer (-80 ° C). miRNAs in the brain were extracted using the miRcute miRNA Isolation Kit (TIANGEN Biotech, Beijing, China).
Whole-blood samples were collected with anticoagulant tubes from epilepsy patients (n = 40) and non-epilepsy control (n = 40). Demographic and clinical features of whole-blood samples from the participants are shown in online supplementary Table 1 (see  www. karger.com/doi/10.1159/000496344 for all online suppl. material). The blood samples were immediately centrifuged at a speed of 3,000 rpm for 5 min. The supernatants (plasma) were collected into new RNase-free tubes and stored in an ultra-low temperature freezer (-80 ° C). miRNAs in plasma were extracted using the miRcute Serum/Plasma miRNA Isolation Kit (TIANGEN Biotech). The sample collection and lab conduction were blinded to the grouping.
Animals, Behavior Observation, and Treatments
About 8-week-old male C57BL/6 mice (weighing from 18 to 22 g) from the Animal Center of Xiamen University were housed on a 12/12-h light/dark cycle. Experimental timeline of the treatments is shown in online supplementary Figure 1 . Mice were administered an intraperitoneal injection (i.p.) of KA (15 mg/kg) or saline. Mouse behavior was observed according to Racine's scale [26] . The mice in the KA group developing acute seizure (≥stage IV according to Racine's scale) were further subjected to intracerebroventricular injection (i.c.v.) of antagomir NC or miR-155 antagomir. miRNA antagomir NC is miRNA from a kind of nematode which cannot bind to the target miRNAs. Thus, mice were randomly divided into three groups (8 (see details in online suppl. Table 2 ). Inclusion criteria: 8-weekold healthy male C57BL/6 mice (weighing 18-22 g); mice developed acute seizure (≥stage III according to Racine's scale); mice that developed acute seizure were alive after i.c.v. injection. Exclusion criteria: mice died at any time; mice developed seizure less than Racine's scale III. The study was designed as a singleblinded trial, and the samples were detected by uninformed experimenter.
This study was carried out in accordance with the principles of the Basel Declaration and recommendations of the guidelines for the conduct of research involving animals as established by the Institutional Animal Care and Use Committee at Xiamen University. The protocol was approved by the Institutional Animal Care and Use Committee at Xiamen University.
Intracerebroventricular Injection
As previously described [27] , mice were subjected to miR-155 antagomir or NC injection into the right lateral cerebral ventricle (i.c.v., 0.5 mm posterior to the bregma, 1.0 mm lateral to the midsagittal suture, 2.2 mm below the dura matter) using a 10-μL Hamilton syringe at a speed of 0.3 μL/min in a stereotaxic instrument (RWD Life Science, Shenzhen, China). The syringe was held for 10 min after injection.
EEG Recording
Mice were anesthetized with 3% isoflurane (RWD Life Science). For electroencephalograph (EEG) recording, polyamideinsulated, stainless steel monopolar microelectrodes (0.1 mm in diameter; Plastics One Inc., Roanoke, VA, USA) were inserted into the subcutaneous frontal area of both hemispheres (-1.5 mm bregma, 1.8 mm lateral). The EEGs of all mice were recorded for 2 h after the i.c.v. injection following the method described previously [27] . EEG data were analyzed by Nicolet 1.0 software in which the interference of alternating current was eliminated, and the sensitivity was uniformly adjusted to 20 μV/mm.
Primary Microglia and Astrocyte Culture, Treatments, and Collection of Microglia-Conditioned Medium
Primary microglial cultures were prepared as previously described [28] . In brief, about 4 postnatal day 2 C57BL/6 pups were prepared for mixed glial cultures. Mixed cells were plated onto poly-L-lysine-coated flasks and grown in DMEM supplemented with 10% FBS (Gibco, Life Technologies, USA). Primary astrocyte or microglia culture was then performed as follows.
For primary astrocyte collection, culture medium was changed every 3 days for 7-10 days of mixed glial cell incubation. Astrocytes were then acquired and purified by vigorous shaking flasks in a 37 ° C shaker, at 180 rpm for 2 h. The astrocytes were replated in poly-L-lysine-coated 6-well plates for real-time PCR.
For primary microglia collection, culture medium was changed to DMEM containing 25 ng/mL GM-CSF and 10% FBS the next day. Primary microglial cells were harvested by shaking (200 rpm, 15 min) after another 9-day culture.
For treatments, microglia was preincubated with miR-155 antagomir or NC for 30 min and were then treated with or without KA (50 μM) for 2 or 12 h. The cells were collected for quantitative real-time PCR (qRT-PCR).
For microglia-conditioned medium collection, in some experiments, the treated cells were rinsed thrice with phosphate-buffered saline (PBS) and were then incubated in fresh serum-free DMEM for 24 h. The medium was centrifuged (1,200 g, 10 min) and the supernatants were collected. Collections were filtered through a 0.45-μm filter and were then stored at -80 ° C.
Neuron Culture and Treatment
Neurons were obtained from postnatal day 1-2 C57BL/6 mice as described by us previously [29] . Briefly, hippocampal cells were cultured at 37 ° C in a 5% CO 2 incubator for 24 h with neurobasal medium containing 2% B27 supplement (Invitrogen, Carlsbad, CA, USA), 1% antibiotic-antifungal mixture (Invitrogen), and 0.5 mM L-glutamine (Invitrogen). Neurons were cultured continually for another 7 days, and then incubated in the collected microgliaconditioned medium. Whole-cell action potentials in treated neurons were recorded afterwards.
Whole-Cell Electrophysiological Recording
Microglia-conditioned medium was mixed together with neural basal medium at a ratio of 1: 1 and was then added into the primary neuron (10 days in vitro) for 8 h prior to electrophysiological recording. For whole-cell recording of spontaneous EPSCs (sEPSCs) and sIPSCs, pipette solution contained (in mM): 140 Cs-CH 3 SO 3 , 2 MgCl 2 , 5 TEA-Cl, 10 HEPES, 1 EGTA, 2.5 Mg-ATP, 0.3 Na 2 -GTP, adjusted to pH 7.2-7.4 with CsOH. sEPSCs were recorded at a holding potential of -70 mV, and sIPSCs were recorded at a holding potential of 0 mV. Recording data were collected with Multi-Clamp 700B amplifier (Molecular Devices) using Clampex10 acquisition software (Molecular Devices), filtered at 1 kHz, sampled and digitized with Digidata 1440A (Molecular Devices). Raw data were analyzed off-line with pClamp10.3 software. Frequency and amplitude of sEPSCs and sIPSCs were measured by using the Mini Analysis Program. For evoked spikes recording, the culture cells were perfused with ACSF, and the glass pipette was filled with solution containing (in mM): 140 K-gluconate, 2 MgCl 2 , 0.1 CaCl 2 , 10 HEPES, 1.1 EGTA, 0.3 Na 2 -GTP, Na 2 -ATP, adjusted to pH 7.25 with KOH.
Microglial Iba1 Immunofluorescent Staining
For microglia grown on cover glasses, the culture medium was aspirated, and cells were thoroughly washed with PBS, fixed with 4% PFA in PBS for 30 min, then permeabilized with 0.3% Triton X-100 for 15 min at room temperature (RT). The nonspecific binding sites were blocked with 5% normal goat serum for 30 min at RT. Cells were incubated with the mouse anti-Iba1 primary antibody (1: 100; Wako) overnight at 4 ° C. Cells were then washed three times with PBS and were incubated with the Alexa Fluor 594-conjugated goat anti-mouse secondary antibody (1: 500; Life Technology) for 2 h at RT. Cells were then washed three times with PBS and mounted on object glasses with VECTASHIELD Mounting Medium with DAPI (Vector Lab Inc., Burlingame, CA, USA). The images were captured with an OLYMPUS FV10-ASW confocal microscope (OLYMPUS, Japan). Microglia morphology was determined by Iba1 staining in high-power field.
Fluoro-Jade B Staining
According to the literature [10, 30] , the coronal frozen brain slices (25 μm) were thoroughly washed with PBS and were fixed with 4% PFA in PBS for 30 min at RT. Following permeabilization with 0.3% Triton X-100 for 15 min at RT, the slices were washed three times with PBS and were incubated with 0.0004% FluoroJade B (FJB; Millipore, USA) for 1 h at 4 ° C. After washing with DOI: 10.1159/000496344 PBS, the slices were mounted with the VECTASHIELD Mounting Medium.
FJB stains of at least 3 sections per mouse from 3 mice were selected for quantifying. Degenerative neurons double stained with DAPI and FJB were acquired per high-power field in the hippocampus CA2 region using OLYMPUS FV10-ASW 4.0 Viewer software.
Quantitative Real-Time PCR For miRNA qPCR detection, total miRNA in human blood, human or mouse brain, and primary microglia was extracted using the miRcute miRNA Isolation Kit. Then, the total miRNAs were reverse transcribed to cDNA templates using the miRcute Plus miRNA First-Strand cDNA Synthesis Kit (TIANGEN). The final qPCR reaction mixture 10 µL in volume consisted of 5 µL of SYBR Green Master (Roche, Basel, Switzerland), 0.5 µL of miR-155 or U6 primers (Ribo Bio, Guangzhou, China), 1 µL of the cDNA template (diluted 10 times), and 3.5 µL of RNase-free H 2 O. Amplification parameters were as follows: denaturation at 95 ° C for 15 min, followed by 40 cycles at 94 ° C for 20 s and 60 ° C for 34 s. The set of U6 primers was used as an internal control for each specific mi-RNA amplification.
For total RNA sample qPCR detection, total RNA was extracted by Trizol Reagent (Thermo Fisher Scientific, Waltham, MA, USA) and reverse transcribed to cDNA templates using ReverTra Ace qPCR RT Master Mix (TOYOBO, Japan). The primers for mouse Snx27, il-6, il-1β, and β-actin are listed in Table 1 . The final 10 µL qPCR reaction mixture consisted of 5 µL SYBR Green Master (Roche), 0.5 µL paired primers, 2 µL cDNA template (diluted 10 times), and 2.5 µL RNase-free H 2 O. The set of β-actin primers was used as an internal control for each specific gene amplification.
The real-time value of each sample was averaged and compared using the CT method, where the amount of target RNA ( 2−ΔΔ CT) was normalized to the endogenous β-actin or U6 reference (ΔCT) and then normalized against control levels.
Statistical Analysis
All data were analyzed using GraphPad Prism 5.0 statistical software. Statistical significance was determined by Student's t tests or one-way ANOVA. All clinical data were analyzed by the nonparametric test. p < 0.05 was considered statistically significant. Data in all figures are expressed as mean ± standard error of the mean.
Results

miR-155 Level Was Elevated in the Brain of KA-Induced Seizure Mice and TLE Patients
We first measured miR-155 expression level in the brains of mice intraperitoneally injected with KA or ve- hicle (saline) by qRT-PCR. The results showed that the levels of miR-155 in both the cortex and hippocampus were significantly elevated upon KA treatment, whereas there were not significant changes in the levels of miR-338, miR-200b, or miR-23a (Fig. 1a, b) . Moreover, we found that the miR-155 expression level also dramatically increased in the brain specimens of TLE patients compared to those of non-epilepsy controls (Fig. 1c) .
Silencing of miR-155 Protects against Epileptogenesis in KA-Induced Mice
Since the level of miR-155 markedly increased in KAinduced seizure model mice and TLE patients, we speculated that depletion of miR-155 might have a protective effect. To study this, we injected an antagomir targeting miR-155 and an NC into the mouse brain by i.c.v. administration 6 h after KA administration. As expected, miR-155 antagomir treatment attenuated KA-induced seizure from grade IV-V to grade II-III according to Racine's standards. In addition, miR-155 antagomir treatment markedly improved abnormal EEG recordings induced by KA (Fig. 2a) in the form of a lower spike amplitude and frequency (Fig. 2b) . However, we found that the EEG recording and behavior in mice treated with miR-155 antagomir alone were almost the same as those in scrambled antagomir NC-treated mice, suggesting that miR-155 antagomir alone does not impact mouse behavior or EEG (online suppl Fig. 2) . Furthermore, miR-155 antagomir treatment ameliorated neurodegeneration induced by KA as examined by FJB immunofluorescence assay (Fig. 2c) . Since miR-155 has been reported to negatively regulate the expression level of SNX27, resulting in neurodegeneration [31] , we also checked the expression of SNX27. It was found that the SNX27 level slightly but not significantly decreased upon KA treatment, and it was not affected by the co-treatment with miR-155 antagomir and KA (Fig. 2d) . These results suggest that inhibition of miR-155 may have anti-seizure potential and that SNX27 may only have a marginal effect on epileptogenesis. 
miR-155 Is Abundant in Microglia, and Conditioned Medium from miR-155 Antagomir-Treated Microglia Protects Neuron Activity
To explore the underlying mechanisms of miR-155 in epileptogenesis, the expression profile of miR-155 in different cells in the brain was detected. The expression of miR-155 was abundant in microglia and astrocytes (Fig. 3a) . In addition, miR-155 significantly increased in primary cultured microglia upon KA treatment for 2 or 12 h when compared to the control group (Fig. 3b) . Importantly, we observed that the promoted proinflammatory cytokine (IL-1β and IL-6) expression upon KA treatment was able to be attenuated by miR-155 antagomir treatment (Fig. 3c-d) . Moreover, the morphological change of microglia upon KA treatment was reversed by miR-155 antagomir treatment (Fig. 3e-f) . Together, these results suggest that inhibition of miR-155 may have antiseizure potential by inhibiting microglia activation and subsequent proinflammatory cytokine release.
To determine whether silencing miR-155 in microglia protects neurons, we treated primary neurons with conditioned medium from microglia subjected to KA treatment (KA medium) or KA and miR-155 antagomir cotreatment (KA-miR-155 antagomir medium). Wholecell recording was then performed to record the action potential of neurons. As shown in Figure 4a , spike numbers of neurons treated with KA medium were much higher than those of untreated controls, whereas spike numbers of neurons treated with KA-miR-155 antagomir medium were nearly the same as those of untreated controls and significantly lower than those of neurons treated with KA medium. In addition, neurons treated with KA medium had significantly increased frequencies and spike numbers of sEPSCs and sIPSCs, which were abol- ished in neurons treated with KA-miR-155 antagomir medium (Fig. 4b, c) . Therefore, silencing miR-155 in microglia may protect neuronal function against KA toxicity, possibly by negatively regulating microglia-secreted proinflammatory factors.
miR-155 Level Increased in the Blood of Epilepsy Patients
Emerging evidence has shown that biofluids (cerebrospinal fluid and blood) of patients with epilepsy have different quantities of circulating miRNAs, implying diagnostic biomarker due to their stable complexing with proteins or encapsulation in extracellular vesicles [32] . Given the enhanced expression of miR-155 in epilepsy patients and in the KA-induced animal model, miR-155 is considered to be a novel biomarker for predicting the efficacy of treatment against epilepsy. We then studied whether miR-155 level could also be altered in the blood of an epilepsy patient. Indeed, comparison between 40 epilepsy patients and 40 healthy controls revealed that miR-155 levels in the blood of epilepsy patients were significantly higher than those in controls (Fig. 5) , suggesting that circulating miR-155 may be a potential biomarker for patients with epilepsy.
Discussion
It has been reported that miRNAs are dysregulated in various diseases including epilepsy [8, 12] . Changes in the levels or activity of miRNAs have profound effects on cellular function, which creates dysregulation of an attractive potential disease mechanism in epilepsy. Indeed, several years of research in rodent models have provided strong evidence that acute or recurrent seizures change miRNA expression and function [33] [34] [35] . Altered expression and function of miRNAs in epilepsy affect numerous cellular pathways and processes simultaneously, in which one miRNA presumably regulates many downstream targets and cellular processes at once. Therefore, studies in epilepsy have sparked strong interest in miRNA defects as disease mechanisms and potential therapeutic targets in epilepsy.
In this study, we reported the identification of miR-155 as a seizure-regulated miRNA and demonstrated that silencing of miR-155 protected against KA-evoked seizures and the associated pathological hallmarks of epilepsy. miR-155 is highly expressed in both activated B and T cells and in monocytes/macrophages. It has been shown that miR-155 plays critical roles in various physiological and pathological processes such as hematopoietic lineage differentiation, immunity, inflammation, viral infections, cancer, cardiovascular disease, and Down syndrome [36] [37] [38] . Recently, miR-155 expression was found to be upregulated in the seizure-related acute and chronic stages of mesial TLE (MTLE) in the immature rat model as well as in children with MTLE [39] . Another study also showed that miR-155 antagonist could protect against lithiumpilocarpine-induced status epilepticus in mice through activating BDNF [40] . Moreover, it has also been recently reported that miRNA-155 expression was evidently higher in patients with TLE than that in patients of the normal volunteers group, and miRNA-155 contributed to the occurrence of epilepsy through the PI3K/Akt/ mTOR signaling pathway [41] . Our results are consistent with these findings, and here we found that miR-155 was much more abundantly expressed in glial cells than in neurons, and only miR-155, not miR-338, miR-200b or miR-23a, in both cortex and hippocampus was significantly elevated upon KA treatment in the brain and identified the protective effects of miR-155 antagomir in KAinduced seizure. However, we failed to find the potential of Snx27, a known target gene of miR-155, in this model. Given the abundant expression of miR-155 in microglia, the exact molecular mechanism underlying microglial miR-155 in epilepsy was then evaluated.
Microglia, which account for 5-10% of the total cell population in mammalian brains, play important roles in the brain innate immune system [42] . As in other neurological diseases, there are dramatic observations with microglia morphological activation and associated inflamma- tion in epilepsy [3, [43] [44] [45] . In the current study, we found that proinflammatory cytokines, such as IL-1β and IL-6, were dramatically decreased in response to miR-155 antagomir treatment in KA-treated microglia, accompanied with the morphological change. Furthermore, microgliaconditioned medium collected from miR-155 antagomir treatment significantly attenuated the excitability of neurons (sEPSCs and sIPSCs), suggesting that modulation of the miR-155 may be a novel target for anticonvulsant drugs. Multiple studies have reported that miRNA levels in the circulating system were altered in correlation with certain pathological conditions, suggesting that circulating mi-RNA might become biomarkers for such diseases, including epilepsy [32, [46] [47] [48] [49] . For example, in one genome-wide circulating miRNA expression profiling study, miR-106b-5p was found to have the best diagnostic value for epilepsy [50] . Another study revealed that miR-301a-3p had the best diagnostic value for drug-resistant epilepsy [51] . Very recently, studies have identified miR-27a-3p, miR-328-3p, and miR-654-3p with biomarker potential in plasma [52] . Although numerous studies on epilepsy have provided plausible evidence that miRNAs play a role in the pathogenesis of this disease, few studies assessed miRNA expression in human brain tissues or blood samples. Here, we found that the miR-155 level in epilepsy patients was significantly higher than in healthy controls, implying that circulating miR-155 might be a potential biomarker for patients with epilepsy. Our findings are in line with new evidence suggesting that miR-155 level is enhanced in KAinduced animal models and people with epilepsy. Nevertheless, the exact diagnostic value of miR-155 in epilepsy, as well as whether miR-155 level changed in the blood of different types of epilepsy require further scrutiny.
Our studies demonstrate that miR-155 is a crucial determinant of microglia-mediated neuronal activity and that silencing of miR-155 may lead to protective effects in epileptogenesis. Although it remains to be identified whether miR-155 affects neurons directly by targeting genes, such as Csf1r, C8orf4, Tlr6, or Pea15a, our results demonstrate that it is possible to inhibit miR-155 expression in conditions where miR-155 level is abnormal. In particular, these results indicate that circulating miR-155 may be a potential biomarker for patients with epilepsy and that targeting miR-155 may represent a novel therapeutic approach to combat microglial dysfunction associated with chronic inflammation-related neurological diseases such as epilepsy.
Together, these results indicate that miR-155 regulates neuroinflammation in microglia and suggest that microglial miR-155 may be a novel target for anticonvulsant intervention. However, uncovering whether miR-155 regulates the recurrent activity of chronic epilepsy still needs further investigation, and further experiments need to be done to confirm the role of microglia-derived miR-155 in epilepsy. In addition, given that the expression of miR-155 is also increased in astrocytes, it will be interesting to explore whether miR-155 in astrocytes also plays a role in epileptogenesis.
